Lamivudine

Generic Name
Lamivudine
Brand Names
Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
Drug Type
Small Molecule
Chemical Formula
C8H11N3O3S
CAS Number
134678-17-4
Unique Ingredient Identifier
2T8Q726O95
Background

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication

For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions
Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
10
Registration Number
NCT00000899
Locations
🇺🇸

Univ of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

Duke Univ Med Ctr, Durham, North Carolina, United States

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Phase 1
Completed
Conditions
HIV Infections
Pregnancy
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
26
Registration Number
NCT00000878
Locations
🇺🇸

Los Angeles County - USC Med Ctr, Los Angeles, California, United States

🇺🇸

Univ of Chicago Children's Hosp, Chicago, Illinois, United States

🇺🇸

Children's Hosp of Boston, Boston, Massachusetts, United States

and more 17 locations

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-05-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
200
Registration Number
NCT00000870
Locations
🇺🇸

The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States

🇺🇸

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

🇺🇸

Case CRS, Cleveland, Ohio, United States

and more 17 locations

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT00000952
Locations
🇺🇸

Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States

🇺🇸

The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States

🇺🇸

HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States

and more 9 locations

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Phase 1
Completed
Conditions
HIV Infections
Pregnancy
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
14
Registration Number
NCT00000888
Locations
🇺🇸

Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States

🇺🇸

Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States

🇺🇸

Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States

and more 2 locations

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Phase 4
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
200
Registration Number
NCT00002179
Locations
🇺🇸

LAC - USC Med Ctr, Los Angeles, California, United States

🇺🇸

Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States

🇺🇸

Beth Israel Deaconess Med Ctr - East Campus, Boston, Massachusetts, United States

and more 14 locations

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Phase 4
Completed
Conditions
HIV Infections
Lipodystrophy
First Posted Date
2000-08-28
Last Posted Date
2010-03-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registration Number
NCT00006190
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

Phase 1
Completed
Conditions
HIV Infection
First Posted Date
1999-11-04
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
42
Registration Number
NCT00001644
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Lamivudine for Chronic Hepatitis B

First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
60
Registration Number
NCT00001457
Locations
🇺🇸

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy